Daniel Smith, MD
Pulmonary Disease · Chattanooga, TNNPI 1043209265
Payments from drug & device makers
Across 480 payments — averaging $44.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$12K
- Viiv Healthcare Company$2K
- Jazz Pharmaceuticals Inc.$1K
- Axsome Therapeutics, Inc.$931
- AstraZeneca$917
- Mylan Specialty L.p.$898
- plus $4K from 32 others
What the payments were for
- Speaking & faculty fees$11,50054%
- Food & beverage$9,77346%
- Education$1451%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 122 | $12,206 |
| Viiv Healthcare Company | 1 | $1,600 |
| Jazz Pharmaceuticals Inc. | 55 | $1,326 |
| Axsome Therapeutics, Inc. | 29 | $931 |
| AstraZeneca | 41 | $917 |
| Mylan Specialty L.p. | 55 | $898 |
| Harmony Biosciences LLC | 39 | $818 |
| Sanofi | 15 | $371 |
| Avadel CNS Pharmaceuticals, LLC | 13 | $283 |
| Grifols USA, LLC | 14 | $253 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $231 |
| Idorsia Pharmaceuticals US Inc | 17 | $201 |
| Boehringer Ingelheim | 10 | $194 |
| Regeneron Healthcare Solutions, Inc. | 8 | $181 |
| UCB, Inc. | 6 | $115 |
| Insmed, Inc. | 5 | $113 |
| Merck | 5 | $82 |
| Mallinckrodt Hospital Products Inc. | 3 | $74 |
| Viatris Specialty LLC | 4 | $71 |
| Electromed, Inc. | 3 | $69 |
| Inspire Medical Systems, Inc. | 3 | $59 |
| Eisai Inc. | 3 | $56 |
| Shire North American Group Inc | 2 | $37 |
| 3b Medical, Inc. | 2 | $37 |
| Philips North America LLC | 1 | $28 |
| ZOLL Respicardia, Inc. | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Inogen, Inc. | 2 | $24 |
| Resmed Corp | 1 | $22 |
| Verona Pharma, Inc. | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Baxter Healthcare | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Circassia Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$10,147
- SUNOSI$473
- AIRSUPRA$125
- Yupelri$124
- BREZTRI$116
How this compares
$21,418 in reported general payments places this provider in the 80th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 775 | $639,779 |
| Breo ElliptaFluticasone/Vilanterol | 305 | $146,805 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $117,630 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 77 | $46,328 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $42,884 |
| SunosiSolriamfetol Hcl | 32 | $28,760 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $12,970 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $7,366 |
| Spiriva HandihalerTiotropium Bromide | 13 | $7,172 |
| Armodafinil | 108 | $6,922 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 195 | $6,613 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $6,080 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $5,693 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,807 |
| BreynaBudesonide/Formoterol Fumarate | 22 | $3,783 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $12,206 | $840,2781,173 claims |
| Grifols USA, LLCProlastin C | $253 | $117,63013 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $917 | $46,69156 claims |
| Axsome Therapeutics, Inc.Sunosi | $931 | $28,76032 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat, Striverdi Respimat | $194 | $21,80336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Chattanooga
- Krishnendu BhadraChattanooga$631K
- Michael CzarneckiChattanooga$348K
- Carlos BaleeiroChattanooga$265K
- Vincent ViscomiChattanooga$28K
- Fabien MaldonadoNashville$2.5M
- Aaron MilstoneFranklin$2.4M
- John SwisherKnoxville$2.3M
- James TolleNashville$2.3M
- Lisa LancasterNashville$1.6M
- Ivan RobbinsNashville$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.